NCT04232761Completed
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
Safety and Effectiveness of Xofigo® (Radium-223 Dichloride) in Routine Clinical Practice Settings in Taiwan
Source: ClinicalTrials.gov · Last updated 17 Jul 2024
Brief summary (registry, in English)
In this observational study researchers want to gather more information about safety and survival in patients suffering from castration-resistant prostate cancer (CRPC) which has spread to the bone and were treated with radium-223 in routine clinical practice in Taiwan. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 194 (actual)
- First submitted
- 15 Jan 2020
- Start date
- 7 Jul 2020
- Primary completion date
- 29 Apr 2024
- Lead sponsor
- Bayer
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT04232761
What you commit to
- Study type: Observational
- Participants enrolled: 194
- From 7 Jul 2020 to the primary completion date, 29 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously treated with Radium-223 for any reason
Other
- Currently treated in clinical trials including other Radium-223 studies or planned participation in an investigational program with interventions outside of routine clinical practice during the study period
Who the study is looking for
- Histologically or cytologically confirmed castration-resistant adenocarcinoma of the prostate with bone metastases
- Treatment decision for Radium-223 according to local label needs to be made independent from and before patient enrollment in the study by the investigator
- No contra-indications according to the local marketing authorization
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Taiwan | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.